EU extends Remicade indications
Schering-Plough and Centocor have been granted marketing authorizationin the European Union for the combination of their Remicade (infliximab) antibody with methotrexate for the improvement in physical function of patients with rheumatoid arthritis, as well as for reducing the rate of progression of joint damage when the response to disease-modifying drugs, including methotrexate, has been inadequate.
The expanded approval, which has also been granted in the USA, is based on the results of the ATTRACT study (Marketletter September 27, 1999).
Meanwhile, S-P has filed for approval to market PEG-Intron (pegylated interferon-alfa-2b) in combination with ribavirin for hepatitis C. Ribavirin is already approved for use in combination with the firm's non-pegylated version, Intron A, under the Rebetron brand name (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze